Dermata Therapeutics (DRMA) SVP adds 1,000 shares in insider buy

Rhea-AI Filing Summary

Dermata Therapeutics, Inc. senior vice president of regulatory affairs Maria E. Bedoya-Toro Munera bought 1,000 shares of common stock in an open-market transaction at $1.27 per share on February 17, 2026. Following this purchase, she holds 1,012 shares directly and 34 shares indirectly through the Munera Family Trust.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bedoya-Toro Munera Maria E

(Last) (First) (Middle)

3525 DEL MAR HEIGHTS RD.

#322

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Dermata Therapeutics, Inc. [ DRMA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Regulatory Affairs

3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/17/2026		P		1,000	A	$1.27	1,012	D
Common Stock								34	I	Munera Family Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Gerald T. Proehl, Attorney-in-Fact	03/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Dermata Therapeutics (DRMA) report for Maria E. Bedoya-Toro Munera?

Dermata Therapeutics reported that SVP of regulatory affairs Maria E. Bedoya-Toro Munera bought 1,000 shares of common stock in an open-market transaction. The trade occurred on February 17, 2026, and was disclosed in a Form 4 insider filing.

How many Dermata Therapeutics (DRMA) shares did the SVP buy and at what price?

Maria E. Bedoya-Toro Munera purchased 1,000 Dermata Therapeutics common shares at $1.27 per share. This open-market transaction increased her reported direct ownership to 1,012 shares, as reflected in the Form 4 filing for February 17, 2026.

What are Maria E. Bedoya-Toro Munera’s total reported Dermata (DRMA) holdings after the Form 4?

After the reported transaction, Maria E. Bedoya-Toro Munera holds 1,012 Dermata common shares directly. The filing also shows 34 additional shares held indirectly through the Munera Family Trust, giving insight into both her direct and trust-related positions.

Was the Dermata Therapeutics (DRMA) insider trade a purchase or sale?

The Dermata Therapeutics insider trade was a purchase. Maria E. Bedoya-Toro Munera executed an open-market buy of 1,000 common shares, as indicated by transaction code P and the transaction_direction field showing a buy in the Form 4 data.

What role does the insider in Dermata Therapeutics (DRMA) Form 4 hold at the company?

The reporting person in the Dermata Therapeutics Form 4, Maria E. Bedoya-Toro Munera, serves as SVP, Regulatory Affairs. Her purchase of 1,000 common shares reflects equity ownership by a senior executive involved in the company’s regulatory strategy.

Does the Dermata Therapeutics (DRMA) Form 4 show any indirect share ownership?

Yes. In addition to 1,012 directly held shares, the Form 4 lists 34 Dermata common shares held indirectly through the Munera Family Trust. This entry is classified as indirect ownership, providing additional detail on the insider’s total reported exposure.